mProX™ Human CD19 Stable Cell Line

Ghobadi, Armin. et al. "Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma." Blood advances, 2023.
A pilot investigation was conducted on 14 patients with relapsed diffuse large B-cell lymphoma (DLBCL) or transformed follicular lymphoma who had undergone autologous stem cell transplant (auto-SCT) and received blinatumomab consolidation. Following standard auto-SCT with BEAM conditioning, all 14 patients completed one cycle of post-transplant blinatumomab treatment. Five patients experienced grade 1 cytokine release syndrome (CRS), and no higher-grade CRS or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. Twelve patients achieved complete remission 100 days post auto-SCT, with 50% remaining in remission at one year. The study suggests the safety of blinatumomab consolidation post auto-SCT, highlighting the need for strategies to enhance CD8/CD4 ratios and explore additional consolidation cycles in larger randomized trials to confirm efficacy.
Ghobadi, Armin. et al. "Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma." Blood advances, 2023.
Pubmed: 37871306   DOI: 10.1182/bloodadvances.2023011130

Hao, Yuanyuan. et al. "Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling." Frontiers of medicine, 2023.
Tumor-derived exosomes (TEXs) are known to contain immune suppressive molecules that have a major impact on T-cell dysfunction and antitumor immunity. One promising treatment for hematological malignancies is chimeric antigen receptor (CAR) T-cell therapy, but the effects of lymphoma TEXs on CAR T-cells have not been fully understood. Recent research has shown that B-cell lymphoma-derived exosomes play a role in the activation of CD19-CAR T-cells, but can also induce T-cell apoptosis and inhibit their cytotoxicity. Furthermore, exposure to lymphoma-derived exosomes may lead to the conversion of CAR T-cells into regulatory T-cells (Treg) with increased expression of inhibitory receptors such as PD-1, TIM3, and LAG3. Similar results were observed in CAR T-cells exposed to plasma exosomes from lymphoma patients. However, this negative impact on CAR T-cells can be reversed by blocking transforming growth factor β (TGF-β)-Smad3 signaling with the inhibitor LY2109761. As such, a combination of CAR T-cell therapy and TGF-β inhibitors may serve as a potential novel treatment approach for refractory and relapsed B-cell lymphoma.
Hao, Yuanyuan. et al. "Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling." Frontiers of medicine, 2023.
Pubmed: 37870681   DOI: 10.1007/s11684-023-1010-1